Announcements
- Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
- Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
- Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Tuesday, Crinetics Pharmaceuticals Inc (6Z4:BER) closed at 41.00, 4.59% above its post-IPO low of 39.20, set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 41.00 |
---|---|
High | 41.00 |
Low | 41.00 |
Bid | 40.60 |
Offer | 41.40 |
Previous close | 39.20 |
Average volume | 18.50 |
---|---|
Shares outstanding | 78.74m |
Free float | 75.75m |
P/E (TTM) | -- |
Market cap | 3.45bn USD |
EPS (TTM) | -3.70 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 07:07 BST.
More ▼